Scarica l'app Stockscreener
6.53
3.40%
-0.23
Dopo l'orario di chiusura:
6.20
-0.33
-5.05%
Precedente Chiudi:
$6.76
Aprire:
$6.64
Volume 24 ore:
579.11K
Relative Volume:
2.79
Capitalizzazione di mercato:
$477.39M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+6.35%
1M Prestazione:
-15.74%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$6.38
$6.68
Intervallo di 1 settimana:
$6.1401
$6.83
Portata 52W:
$5.33
$7.9999
Niagen Bioscience Inc Stock (NAGE) Company Profile
Nome
Niagen Bioscience Inc
Settore
Industria
Telefono
310-388-6706
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Confronta NAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
6.53 | 477.39M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-08-16 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Iniziato | ROTH Capital | Buy |
| 2019-10-16 | Iniziato | Oppenheimer | Outperform |
| 2019-02-14 | Iniziato | B. Riley FBR | Buy |
| 2017-11-27 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-03 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
Supplement Maker Rebrands - Los Angeles Business Journal
Robert Fried Exercises Options, Realizes $173K - Benzinga
Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs - marketscreener.com
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire
Niagen Bioscience maintains stability amid tariffs By Investing.com - Investing.com South Africa
Niagen Bioscience Stands Firm Despite Global Tariff Concerns - Finimize
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments - MarketScreener
Niagen Bioscience maintains stability amid tariffs - Investing.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues - simplywall.st
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - MarketScreener
H.C. Wainwright holds $11 target on Niagen Bioscience stock By Investing.com - Investing.com Canada
H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE) - simplywall.st
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - MarketScreener
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results - MarketScreener
Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks
Niagen Bioscience secures new patent for NAD+ precursors - Investing.com
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire
Niagen Bioscience, Inc. Rings the Closing Bell - Nasdaq
ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com
Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian
ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal
Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks
ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries - NutraIngredients-USA.com
ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - insights.citeline.com
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Bluefield Daily Telegraph
ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com
Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - Stock Titan
ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha
ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript - Insider Monkey
ChromaDex Reports Strong 2024 Financial Performance - TipRanks
When Will ChromaDex Reveal Its Q4 Performance? Key Date for NAD+ Leader's Financial Results - Stock Titan
ChromaDex to Present at Lytham Partners Healthcare Summit, Showcasing NAD+ Research Advances - StockTitan
Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire
Thorne acquires brain health formula partner in $5 million deal - SupplySide Supplement Journal
The proper role of pre-blends of nutrients in production of dietary supplements - SupplySide Supplement Journal
FDA Criminal Office Said to Be Examining Drug Ostarine in Dietary Supplements - SupplySide Supplement Journal
Technology disruption in the dietary supplement industry - SupplySide Supplement Journal
IV and Injection Offerings to Additional Leading Wellness Clinics - Business Wire
GMP Requirements for Softgels - SupplySide Supplement Journal
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions - Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 - Business Wire
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) - Business Wire
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen - Business Wire
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable - simplywall.st
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 - Business Wire
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award - Business Wire
(Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD - Business Wire
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market - Business Wire
Niagen Bioscience Inc Azioni (NAGE) Dati Finanziari
Non sono disponibili dati finanziari per Niagen Bioscience Inc (NAGE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):